Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04701476 · ClinicalTrials.gov registry record · Phase 2
TATE and Pembrolizumab (MK3475) in mCRC and NSCLC
A Phase 2 study of Colorectal Cancer; Lung Cancer, sponsored by Teclison.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 110
- Enrollment target
- 3
- Study locations
NCT04701476: Recruiting Phase 2 study of Colorectal Cancer; Lung Cancer, sponsored by Teclison.
NCT04701476 is a Phase 2 study of Colorectal Cancer; Lung Cancer that is actively recruiting participants, run by Teclison. The registered enrollment target is 110 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (17% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04701476, a Phase 2 study of Colorectal Cancer; Lung Cancer, is actively recruiting participants, sponsored by Teclison.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 110 participants
- Enrollment target
- 3
- Study locations
Study Summary
Patients with refractory metastatic colorectal cancer or non-small cell lung cancer with liver metastasis treated with Trans-arterial Tirapazamine Embolization along with Pembrolizumab.
Primary Outcome
From the first day of treatment to death
Conditions Studied
Interventions
- DRUG TATE and pembrolizumab
- DRUG TAS-102 pill
- DRUG Regorafenib Pill
Study Locations (3)
Other
- China Medical University Hsinchu Hospital - Hsinchu
- Chung Shan Medical University Hospital - Taichung
California
- University of California, Irvine Medical Center - Orange
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2021-05-20 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 2 |
What NCT04701476 shows while recruiting
NCT04701476 is an interventional study that assigns participants to a tested intervention. The registered 110 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (17% lower).
The record links to 1 condition, with Colorectal Cancer; Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which TATE and pembrolizumab is the first listed.
NCT04701476 reports a single indexed study location in Other, California.
Frequently Asked Questions
What is clinical trial NCT04701476 about?
NCT04701476 is a clinical study titled "TATE and Pembrolizumab (MK3475) in mCRC and NSCLC". Patients with refractory metastatic colorectal cancer or non-small cell lung cancer with liver metastasis treated with Trans-arterial Tirapazamine Embolization along with Pembrolizumab.
What is the current status of trial NCT04701476?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 110 participants. The study started on 2021-05-20. Estimated completion is 2025-12-31.
What conditions does trial NCT04701476 study?
This clinical trial studies the following conditions: Colorectal Cancer; Lung Cancer.
What interventions are being tested in trial NCT04701476?
The interventions under investigation include: TATE and pembrolizumab (DRUG), TAS-102 pill (DRUG), Regorafenib Pill (DRUG).
Who is sponsoring clinical trial NCT04701476?
This trial is sponsored by Teclison, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04701476 being conducted?
This trial has 3 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04701476's enrollment target sits among peer trials
110 632nd of 2000 higher than 1,361 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01530373 · 110 participants · Phase 2
Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients
- NCT02379377 · 110 participants · Phase 1
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
- NCT02411773 · 110 participants · Phase 1
Sympatholysis in Chronic Kidney Disease
- NCT03190941 · 110 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI